Pancreatic Cancer Research

ResearcherHammersmith HospitalActive in the last 2 years

Harpreet Singh Wasan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6268-2030; OpenAlex author ID A5063738443. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
122
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 19

  1. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  2. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  3. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  4. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.igie.2024.06.005↗
  5. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  6. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… First author DOI 10.1016/j.esmoop.2021.100356↗
  7. Immunological combination treatment holds the key to improving survival in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03332-5↗
  8. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  9. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  10. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Last author DOI 10.1080/15384047.2018.1504718↗
  11. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. Last author DOI 10.21037/jgo.2018.01.14↗
  12. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  13. Pancreatic cancer: current understanding of molecular and genetic aetiologies. First author DOI 10.1136/postgradmedj-2014-133161↗
  14. Pancreatic cancer: current management and treatment strategies. Co-author DOI 10.1136/postgradmedj-2014-133222↗
  15. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2014.04.002↗
  16. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Co-author DOI 10.1016/s1470-2045(13)70021-4↗
  17. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  18. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective eval… First author DOI 10.1200/jco.2013.51.0826↗
  19. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul J. Ross · 5 shared papers, 2017–2025 · strength 0.52
  2. Daniel H. Palmer · 5 shared papers, 2017–2025 · strength 0.46
  3. Juan W. Valle · 5 shared papers, 2017–2025 · strength 0.46
  4. Pascal R. Hammel · 4 shared papers, 2017–2025 · strength 0.44
  5. Long R. Jiao · 4 shared papers, 2015–2023 · strength 0.40
  6. Yuk Ting Ma · 4 shared papers, 2017–2025 · strength 0.39
  7. Paula Ghaneh · 4 shared papers, 2017–2025 · strength 0.39
  8. Thilo Hackert · 4 shared papers, 2017–2025 · strength 0.39
  9. John P. Neoptolemos · 4 shared papers, 2017–2025 · strength 0.39
  10. David Cunningham · 4 shared papers, 2017–2025 · strength 0.39
  11. Christopher Michael Halloran · 4 shared papers, 2017–2025 · strength 0.39
  12. Adnan M. Nagrial · 3 shared papers, 2013–2024 · strength 0.34
  13. Nam Quoc Nguyen · 2 shared papers, 2022–2024 · strength 0.31
  14. Daniel Gerald Croagh · 2 shared papers, 2022–2024 · strength 0.31
  15. Somnath Mukherjee · 3 shared papers, 2013–2024 · strength 0.31
  16. Christoph Springfeld · 2 shared papers, 2023–2025 · strength 0.29
  17. Thankamma Ajithkumar · 2 shared papers, 2022–2024 · strength 0.29
  18. Gary Middleton · 3 shared papers, 2017–2025 · strength 0.27
  19. Olusola Olusesan Faluyi · 3 shared papers, 2017–2025 · strength 0.27
  20. Bengt L. G. Glimelius · 3 shared papers, 2017–2025 · strength 0.27
  21. Tim Meyer · 3 shared papers, 2017–2025 · strength 0.27
  22. Pippa G. Corrie · 2 shared papers, 2020–2024 · strength 0.23
  23. Markus Wolfgang Büchler · 3 shared papers, 2017–2023 · strength 0.22
  24. Derek A O'Reilly · 3 shared papers, 2017–2023 · strength 0.22
  25. Tim Maughan · 2 shared papers, 2013–2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.